Follow The Filings

MTNB Matinas Biopharma

Matinas Biopharma earnings company data as of 4:47 AM ET 10/22

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 9 Nov EPS — — —
Rev — — —
FY2026 Q2 13 Aug EPS — -0.21 —
Rev — — —

Insider trades

Open-market buys and sales by MTNB's executives, directors and 10% owners in the last 12 months, from their Form 4s

All MTNB insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales

No open-market buys or sales on file.

Also filed in the last 12 months, not counted as buying or selling: 3 option exercises.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 3.03,5.03,9.01
8-K 8.01
8-K 3.01,8.01,9.01
SCHEDULE 13D/A —
10-Q
8-K 1.02
SCHEDULE 13G —
8-K 1.01,3.02,3.03,5.01,5.02,5.03,7.01,8.01,9.01
8-K 3.01,8.01,9.01
424B7
10-Q
8-K 3.01,9.01
10-K
8-K 5.02
8-K 5.02,9.01
8-K 5.02
SCHEDULE 13G/A —
10-Q
SCHEDULE 13D/A —
SCHEDULE 13G —
8-K 1.01,3.02,9.01
SCHEDULE 13G/A —
10-Q
8-K 5.03,9.01
8-K 5.02,5.07,9.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.